RBC Capital Markets上调ResMed股票评级（RMD:NYSE）
· seekingalpha.com
ResMed（RMD）股价上涨，因RBC Capital Markets将该股评级上调至“跑赢大盘”，并将目标价上调至262美元，理由是该公司2026财年第四季度业绩表现积极。点击此处了解更多。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...